**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 73953

**Manuscript Type:** LETTER TO THE EDITOR

**Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”**

Kang YB *et al*. Gut microbiome and nivolumab in HCC

Yong-Bo Kang, Yue Cai

**Yong-Bo Kang, Yue Cai,** Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Jinzhong 030600, Shanxi Province, China

**Author contributions:** Kang YB and Cai Y wrote the letter and conceived the manuscript; Kang YB supervised the manuscript drafting and reviewed the literature data; and all authors contributed important intellectual content during manuscript drafting or revision.

**Corresponding author: Yong-Bo Kang, PhD, Associate Professor,** Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Wenhua Street, Jinzhong 030600, Shanxi Province, China. 657151276@qq.com

**Received:** December 10, 2021

**Revised:** January 14, 2021

**Accepted: April 24, 2022**

**Published online:**

**Abstract**

Recently, we read the article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” with interest, and it is preliminary suggested that gut microbiota is closely related to therapeutic effect of nivolumab. Based on the meaningful results of this article, several valuable research directions are proposed to enhance the therapeutic effect of immune checkpoint inhibitors on advanced hepatocellular carcinoma.

**Key Words:** Gut microbiome; Immunotherapy; Immune checkpoint inhibitor resistance; Probiotics; Faecal microbiota transplantation; Hepatocellular carcinoma; Prognosis

Kang YB, Cai Y. Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”. *World J Gastroenterol* 2022; In press

**Core Tip:** Wereadthe article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” with interest, and it is preliminary suggested that the gut microbiota is closely related to therapeutic effect of nivolumab. Future research should pay attention to the relationship between the gut microbiota and therapeutic effect of immune checkpoint inhibitors (ICIs) on advanced hepatocellular carcinoma and the way of regulating the gut microbiota to improve the therapeutic effect of ICIs.

**TO THE EDITOR**

We read with interest the article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”[1], in which the authors analyzed and summarized the correlation between gut bacterial composition and the prognosis of nivolumab therapy in hepatocellular carcinoma (HCC) patients. The highlight of this article was that gut microbiota composition and diversity of responders differed significantly from those of non-responders following nivolumab therapy. Several intestinal bacterial species such as *Citrobacter freundii, Azospirillum species*, and *Enterococcus durans* were specific to the responders. Moreover, a higher *Prevotella/Bacteroides* ratio and the presence of *Akkermansia species* can serve as predictive markers of response. Altogether, the study not only demonstrated that the therapeutic effect of nivolumab has something to do with the composition of the gut microbiota in advanced HCC patients, but also provided some inspiration for future research direction.

In our opinion, it is of importance to underline that the relationship between the therapeutic effect of various immune checkpoint inhibitors (ICIs) such as pembrolizumab, nivolumab atezolizumab, durvalumab, and avelumab on HCC and the gut microbiota. At present, the response rates to ICIs are very low in advanced HCC. To be specific, the response rate to ICI monotherapy is merely 15%-23%, which is increased to approximately 30% after combination treatment[2]. How to improve the effectiveness of ICI treatment is essential and has been extensively investigated. While the human gut microbiota has been shown to be associated with clinical responses to ICIs in HCC[3], the available data in this field remain limited and the relevant scientific work is only in the initial stage. Thus, more research is required in the future. First, clinical studies with large sample sizes are needed to further clarify the relationship between the gut microbiota and the therapeutic effect of various ICIs. At the same time, which types of gut microbiota are suitable for which ICIs should also be figured out. Furthermore, construction based on the gut microbiota can function as a prognostic marker for the response to various ICI therapies. These results will provide clinicians with a valuable reference for rational use of ICIs and personalized precision therapy. Second, the mechanism by which the gut microbiota promotes the therapeutic effect of various ICIs needs to be further studied, with the focus on key pathways such as intestinal mucosal barrier function, bacterial metabolites, and microorganism-related molecular patterns, thus being conducive to discovering how to enhance the therapeutic effect of various ICIs by targeting the gut microbiota. Third, probiotics, prebiotics, synbiotics, and antibiotics may represent innovative, safe, and low-cost strategies for promoting the therapeutic effect of various ICIs[4]. In this respect, it is of necessity to determine which beneficial bacteria and harmful bacteria are bound up with the therapeutic effects of which ICIs. Meanwhile, it will also be significant to confirm how probiotics, prebiotics, synbiotics, and antibiotics alter the composition of the gut microbiota and how relevant it is to the therapeutic effect of various ICIs. In other words, these results will contribute to the identification of probiotics, prebiotics, synbiotics, and antibiotics that may increase the efficacy of ICIs when being used in combination. Last but not least, faecal microbiota transplantation (FMT) may be a direct and superior approach to enhancing the therapeutic effect of various ICIs through modulating the gut microbiota in human beings. Considering that, it is extremely valuable to explore the therapeutic method of FMT in combination with ICIs. Besides, the optimal gut microbiota composition for enhancing the therapeutic effect of various ICIs should be recognized. On this basis, it is of great importance to choose the right donors[5].

In summary, based on the meaningful research results of this article, it is expected that readers can pay attention to the relationship between the gut microbiota and therapeutic effect of ICIs on advanced HCC and the method of regulating the gut microbiota to improve the therapeutic effect of ICIs.

**REFERENCES**

1 **Chung MW**, Kim MJ, Won EJ, Lee YJ, Yun YW, Cho SB, Joo YE, Hwang JE, Bae WK, Chung IJ, Shin MG, Shin JH. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients. *World J Gastroenterol* 2021; **27**: 7340-7349 [PMID: 34876793 DOI: 10.3748/wjg.v27.i42.7340]

2 **Pinter M**, Jain RK, Duda DG. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. *JAMA Oncol* 2021; **7**: 113-123 [PMID: 33090190 DOI: 10.1001/jamaoncol.2020.3381]

3 **Li L**, Ye J. Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study. *Medicine (Baltimore)* 2020; **99**: e21788 [PMID: 32925716 DOI: 10.1097/MD.0000000000021788]

4 **Kang Y,** Cai Y, Yang Y. The gut microbiome and hepatocellular carcinoma: Implications for early diagnostic biomarkers and novel therapies. *Liver Cancer* 2021 [DOI: 10.1159/000521358]

5 **Kang YB**, Cai Y. Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. *World J Gastroenterol* 2021; **27**: 5362-5375 [PMID: 34539138 DOI: 10.3748/wjg.v27.i32.5362]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review started:** December 10, 2021

**First decision:** January 8, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gorrell MD, Australia; Yu L, Singapore **S-Editor:** Wang JJ **L-Editor:** Wang TQ **P-Editor:**